<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01298830</url>
  </required_header>
  <id_info>
    <org_study_id>CM GLP-1/01</org_study_id>
    <secondary_id>2007-004516-31</secondary_id>
    <nct_id>NCT01298830</nct_id>
  </id_info>
  <brief_title>GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage</brief_title>
  <official_title>GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CellMed AG, a subsidiary of BTG plc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CellMed AG, a subsidiary of BTG plc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety of GLP-1 CellBeads® in patients with
      space-occupying intracerebral hemorrhage.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Need for improvement of study medication. Safety data collected sufficient. No further gain in
    knowledge expected.
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The objective of this study is to assess the safety of GLP-1 CellBeads® in patients with space-occupying intracerebral hemorrhage</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurological conditions</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Intracerebral Hemorrhage (ICH)</condition>
  <arm_group>
    <arm_group_label>GLP-1 CellBeads</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1 CellBeads</intervention_name>
    <description>GLP-1 CellBeads are alginate microcapsules containing allogenic mesenchymal cells, transfected to secrete Glucagon like peptide-1. By implantation into brain tissue cavity after surgical evacuation of the hematoma, a volume of 500μl GLP-1 CellBeads which equals approximately 2330 GLP-1 CellBeads resulting in a total number of approximately 7.8 million cells is administered to the patient. The cells are removed by second surgery after a 14 days treatment period.</description>
    <arm_group_label>GLP-1 CellBeads</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of intracerebral hemorrhage or subarachnoid hemorrhage in
             conjunction with ICH by cranial computed tomography (CCT) or Magnetic Resonance
             Tomography (MRT)

          -  Patients who need by judgement of a clinical neurologist or neurosurgeon surgical
             removal of the blood clot due to its space-occupying effects

          -  Age greater or equal 18 years for men

          -  Age greater or equal 18 years for women if confirmed infertility (e.g. hysterectomy or
             surgical sterilisation at least 3 months before study start)

          -  For all other women age greater or equal 50 years with last menstrual bleeding at
             least one year before study start

          -  Minimum hematoma diameter of 2 cm as measured in baseline CCT or MRT

          -  Signed, written informed consent of patient or consent/assertion from the patient's
             legally acceptable representative/affiliated if the patient is unable to provide
             informed consent

        Exclusion Criteria:

          -  Participation in any other clinical trial within the past 3 months or ongoing

          -  Occurrence of inconsistency with initial diagnosis at baseline during surgery of the
             patient leading to unfulfilled inclusion criterion Hemorrhage secondary to tumour or
             trauma

          -  Patients with a cerebellar hemorrhage or extension of a supratentorial hemorrhage into
             the brainstem

          -  Patients with severe pre-existing physical or mental disability or severe comorbidity
             that interferes with the assessment of outcome

          -  Allergy to contrast media (MRT)

          -  Acute infection

          -  Muscular, neurological, or vascular insufficiency of the respective tissue

          -  Polypropylene incompatibility

          -  Acute immunosuppressive medication

          -  Patient after organ transplantation

          -  Patient with immune depression

          -  Patients with a high probability of spontaneous recovery or showing rapidly improving
             signs

          -  Patients with extensive intracranial hemorrhages or with deep hemispheric localisation
             of the clots

          -  Patients whose diagnosis of ICH is uncertain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Brinker, Prof. Dr.med.</last_name>
    <role>Study Chair</role>
    <affiliation>International Neuroscience Institute Hanover</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurochirurgische Klinik und Neurologische Klinik des Universitätsklinikums Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurochirurgische Klinik der Universität Erlangen-Nürnberg</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurochirurgie Klinikum Bogenhausen Akademisches Lehrkrankenhaus der Technischen Universität München</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Region Hannover Krankenhaus Nordstadt, Klinik für Neurologie</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Neuroscience Institute</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurochirurgie Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2011</study_first_posted>
  <last_update_submitted>March 25, 2013</last_update_submitted>
  <last_update_submitted_qc>March 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2013</last_update_posted>
  <responsible_party>
    <name_title>Dr. med. Peter Geigle / CEO</name_title>
    <organization>CellMed AG</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

